金城醫藥(300233.SZ)下修業績預吿：2021年度預盈0.9億元-1.15億元
格隆匯3月16日丨金城醫藥(300233.SZ)發佈2021年年度業績預吿修正公吿，此前披露，預計2021年度歸屬於上市公司股東的淨利潤區間為盈利1.4億元–1.7億元，扣除非經常性損益後的淨利潤區間為盈利1.05億元–1.45億元。
修正後，預計2021年度歸屬於上市公司股東的淨利潤0.9億元-1.15億元，扣除非經常性損益後的淨利潤0.65億元-0.95億元。
業績修正原因：近日公司全資子公司北京金城泰爾製藥有限公司(“金城泰爾”)收到北京市藥品監督管理局第五分局下發的《北京市藥品監督管理局責令改正通知書》，要求金城泰爾在2022年4月30日前按要求完成匹多莫德分散片(國藥準字 H20060718)上市後臨牀有效性試驗，並向國家藥監局藥審中心提交補充申請且獲受理。
2018年3月20日國家食品藥品監督管理總局發佈了《食品藥品監管總局關於匹多莫德製劑有關事宜的通知》(食藥監藥化管函〔2018〕32號)，要求匹多莫德制劑生產企業儘快啟動臨牀有效性試驗，並於3年內將評價結果報國家藥監局藥審中心。近兩年受疫情影響，研究受試者入組緩慢，匹多莫德臨牀有效性試驗進度低於預期，未能於規定時間上報，截至目前該臨牀有效性試驗仍在進行中。
公司財務部門根據《通知書》要求的整改內容以及該《通知書》對匹多莫德產品銷售的影響進行了審慎評估，認為存在減值風險，需補充計提資產減值準備，從而影響公司 2021 年度遞延所得税資產、資產減值損失、歸屬於母公司股東的淨利潤等財務指標，預計將減少公司歸屬於母公司股東的淨利潤5900萬元左右。
公司將聘請具有證券業務資格的評估機構對相關資產進行減值測試，最終數據將以公司披露的經審計的2021年年度報吿內容為準。由於上述影響發生在資產負債表日至財務報吿批准報出日之間，根據《企業會計準則29號—資產負債表日後事項》的規定作為資產負債表日後調整事項。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
